Annovis Bio (ANVS) Competitors $2.29 +0.01 (+0.48%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$2.30 +0.00 (+0.17%) As of 09/5/2025 06:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANVS vs. ALXO, ENTA, TVGN, CGTX, BIOA, CYBN, DERM, ACTU, FTLF, and CRBUShould you be buying Annovis Bio stock or one of its competitors? The main competitors of Annovis Bio include ALX Oncology (ALXO), Enanta Pharmaceuticals (ENTA), Tevogen Bio (TVGN), Cognition Therapeutics (CGTX), BioAge Labs (BIOA), Cybin (CYBN), Journey Medical (DERM), Actuate Therapeutics (ACTU), FitLife Brands (FTLF), and Caribou Biosciences (CRBU). These companies are all part of the "pharmaceutical products" industry. Annovis Bio vs. Its Competitors ALX Oncology Enanta Pharmaceuticals Tevogen Bio Cognition Therapeutics BioAge Labs Cybin Journey Medical Actuate Therapeutics FitLife Brands Caribou Biosciences Annovis Bio (NYSE:ANVS) and ALX Oncology (NASDAQ:ALXO) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation. Is ANVS or ALXO more profitable? ALX Oncology's return on equity of -115.67% beat Annovis Bio's return on equity.Company Net Margins Return on Equity Return on Assets Annovis BioN/A -206.01% -158.26% ALX Oncology N/A -115.67%-84.82% Which has more volatility and risk, ANVS or ALXO? Annovis Bio has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500. Comparatively, ALX Oncology has a beta of 1.11, suggesting that its stock price is 11% more volatile than the S&P 500. Do institutionals & insiders believe in ANVS or ALXO? 15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 98.0% of ALX Oncology shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 21.0% of ALX Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has higher valuation and earnings, ANVS or ALXO? Annovis Bio is trading at a lower price-to-earnings ratio than ALX Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnovis BioN/AN/A-$24.59M-$2.04-1.12ALX OncologyN/AN/A-$134.85M-$2.20-0.55 Does the media favor ANVS or ALXO? In the previous week, Annovis Bio had 8 more articles in the media than ALX Oncology. MarketBeat recorded 13 mentions for Annovis Bio and 5 mentions for ALX Oncology. ALX Oncology's average media sentiment score of 1.08 beat Annovis Bio's score of 0.49 indicating that ALX Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annovis Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral ALX Oncology 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate ANVS or ALXO? Annovis Bio currently has a consensus price target of $17.33, indicating a potential upside of 656.58%. ALX Oncology has a consensus price target of $3.30, indicating a potential upside of 170.49%. Given Annovis Bio's higher possible upside, equities research analysts plainly believe Annovis Bio is more favorable than ALX Oncology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60ALX Oncology 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 SummaryALX Oncology beats Annovis Bio on 8 of the 13 factors compared between the two stocks. Get Annovis Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANVS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANVS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANVS vs. The Competition Export to ExcelMetricAnnovis BioMED IndustryMedical SectorNYSE ExchangeMarket Cap$44.62M$3.18B$5.83B$21.37BDividend YieldN/A2.27%6.70%3.49%P/E Ratio-1.1221.1076.1529.62Price / SalesN/A466.24557.4869.52Price / CashN/A45.7236.9925.18Price / Book3.429.8711.484.55Net Income-$24.59M-$53.42M$3.29B$999.70M7 Day Performance-1.25%2.93%1.27%0.58%1 Month Performance-14.36%9.85%7.94%5.66%1 Year Performance-70.89%15.74%62.94%17.40% Annovis Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANVSAnnovis Bio2.6958 of 5 stars$2.29+0.5%$17.33+656.6%-70.9%$44.62MN/A-1.123Trending NewsAnalyst ForecastAnalyst RevisionALXOALX Oncology3.9913 of 5 stars$1.17+2.6%$3.30+182.1%-38.7%$62.65MN/A-0.5340News CoveragePositive NewsShort Interest ↓Gap DownENTAEnanta Pharmaceuticals3.8563 of 5 stars$8.40-3.3%$21.67+157.9%-25.3%$179.57M$67.64M-1.94160News CoverageAnalyst ForecastTVGNTevogen Bio3.4897 of 5 stars$0.91+0.8%$10.00+998.9%+92.5%$179MN/A0.003Analyst ForecastShort Interest ↑Gap DownCGTXCognition Therapeutics1.819 of 5 stars$2.43-2.0%$2.83+16.6%+328.9%$178.66MN/A-3.6320Analyst UpgradeAnalyst RevisionBIOABioAge LabsN/A$4.93+2.7%N/AN/A$176.74MN/A0.00N/ACYBNCybin1.8884 of 5 stars$7.48-2.1%$85.00+1,036.4%N/A$176.45MN/A-1.7150Positive NewsDERMJourney Medical1.9175 of 5 stars$7.21-0.8%$12.17+68.7%+49.1%$175.77M$56.13M-18.9790ACTUActuate Therapeutics3.035 of 5 stars$8.44+2.7%$20.33+140.9%+1.1%$175.09MN/A0.0010Positive NewsFTLFFitLife Brands3.1432 of 5 stars$18.62-0.3%$22.00+18.2%+12.0%$174.86M$64.47M22.1720Analyst UpgradeCRBUCaribou Biosciences2.1326 of 5 stars$1.87-3.6%$6.67+256.5%+2.2%$174.14M$9.99M-1.05100 Related Companies and Tools Related Companies ALX Oncology Competitors Enanta Pharmaceuticals Competitors Tevogen Bio Competitors Cognition Therapeutics Competitors BioAge Labs Competitors Cybin Competitors Journey Medical Competitors Actuate Therapeutics Competitors FitLife Brands Competitors Caribou Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ANVS) was last updated on 9/6/2025 by MarketBeat.com Staff From Our PartnersScientists Discover Untapped Energy Source in Heart of USACrash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored6-Figure Target for BTC by 2025The U.S. just announced it's putting GDP data directly onto Bitcoin and Ethereum blockchains. Could this spa...Crypto 101 Media | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredWall Street Legend Issues Urgent AI Stock Warning'Hidden AI' is taking the U.S. stock market by storm.Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredHamilton’s 100-to-1 tradePorter Stansberry has made a career out of bold calls that go against the mainstream narrative — from the 1998...Porter & Company | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annovis Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annovis Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
